Key result
Abciximab reduces periprocedural complications among patients undergoing high-risk coronary angioplasty and demonstrates broad applicability and clinical efficacy during coronary revascularization.
Why the study?
Does abciximab reduce periprocedural complications in patients undergoing percutaneous coronary intervention?
Does abciximab reduce periprocedural complications in patients undergoing percutaneous coronary intervention?
This review highlights the established clinical efficacy and safety of abciximab as a pharmacologic adjunct during percutaneous coronary intervention.
May support adjunctive use in high-risk PCI; leaves open need for contemporary RCTs.
Blockade of the platelet glycoprotein (GP) IIb/IIIa receptor as a therapy for ischemic heart disease was introduced into clinical practice by demonstration that the first of these agents, abciximab, reduces periprocedural complications among patients undergoing high-risk coronary angioplasty. From this initial “proof of concept, ” subsequent clinical evaluation of this agent progressed through a series of large-scale trials, establishing the broad applicability, marked clinical efficacy, and acceptable safety profile of this therapeutic strategy in the setting of percutaneous coronary revascularization. This chapter reviews the clinical experience with this agent as a pharmacologic adjunct to elective or urgent coronary intervention.
No takes yet. Share an insight, caveat, or question.
A. Michael Lincoff (2003) conducted a review in Ischemic heart disease. Abciximab was evaluated. Abciximab reduces periprocedural complications among patients undergoing high-risk coronary angioplasty and demonstrates broad applicability and clinical efficacy during coronary revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: